Tennessee is currently home to 1929 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235
Recruiting
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: The Conrad Pearson Clinic, Germantown, Tennessee
Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Register for Updates
Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation
NCT05945329
Recruiting
Prospective, randomized, controlled study to assess the safety and effectiveness of GalaFLEX LITE™ Scaffold in revision surgery for reduction of capsular contracture recurrence and/or malposition in implant-based breast augmentation patients versus patients undergoing conventional revision surgery with no supportive matrix or acellular dermal matrix (ADM). Subjects will be randomized 2:1 to receive either GalaFLEX LITE™ Scaffold or standard care (no ADM or matrix placement). This study is design... Read More
Gender:
FEMALE
Ages:
Between 22 years and 66 years
Trial Updated:
07/28/2025
Locations: The Plastic Surgery Center of Nashville With HKB, Nashville, Tennessee
Conditions: Capsular Contracture Associated With Breast Implant, Capsular Contracture Grade III, Capsular Contracture Grade IV
Register for Updates
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114
Recruiting
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
07/28/2025
Locations: Shelby Research LLC, Memphis, Tennessee
Conditions: Systemic Lupus Erythematosus
Register for Updates
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749
Recruiting
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
07/28/2025
Locations: West Tennessee Research Institute, Jackson, Tennessee
Conditions: Systemic Lupus Erythematosus
Register for Updates
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT05607004
Recruiting
This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", which help block estrogen from attaching to cancer cells. This study has two parts: a pharmacokinetic part and a treatment part. The PK part (how the body processes the drug) will enroll about 18 participants. All participants will take (Z)-endoxifen capsules dail... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Vanderbilt Ingram Cancer Center, Nashville, Tennessee
Conditions: Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
NCT05433142
Recruiting
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Sarah Cannon Research Institute, LLC, Nashville, Tennessee
Conditions: Clear Cell Renal Cell Carcinoma
Register for Updates
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
NCT05267613
Recruiting
The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.
Gender:
ALL
Ages:
Between 1 year and 11 years
Trial Updated:
07/28/2025
Locations: Research Site, Knoxville, Tennessee
Conditions: Erosive Esophagitis
Register for Updates
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114
Recruiting
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Baptist Cancer Center, Memphis, Tennessee
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647
Recruiting
The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.
Gender:
ALL
Ages:
Between 6 years and 100 years
Trial Updated:
07/28/2025
Locations: West Tennessee Research Institute, Jackson, Tennessee
Conditions: Autoimmunity, Inflammation
Register for Updates
Pulmonary Hypertension Association Registry
NCT04071327
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
07/28/2025
Locations: Ft. Sanders Regional Medical Center, Knoxville, Tennessee
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Register for Updates
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
NCT06965413
Recruiting
The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus (DM). The study comprises of a 4-week screening period; a 48-week core treatment period, where all participants will receive tirzepatide as background treatment and will be randomized to one... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Accellacare of Bristol/ Internal Medicine & Pediatrics, Bristol, Tennessee
Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
Register for Updates
A Study to Improve Skeletal Muscle in Veterans With HIV
NCT06845046
Recruiting
The Department of Veterans Affairs is the largest single provider of medical care to people with HIV in the United States. The condition of excess lipid within and around muscle, termed myosteatosis, predisposes Veterans to physical function decline, frailty, disability, and cardiometabolic diseases such as diabetes and cardiovascular disease. In the investigators current Merit supported cohort, the investigators found that 36% of Veterans with treated HIV and obesity have "myosteatotic type obe... Read More
Gender:
MALE
Ages:
Between 20 years and 80 years
Trial Updated:
07/25/2025
Locations: Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee
Conditions: HIV, Obesity
Register for Updates